- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06791850
Sustaining Home Heart Failure Palliative Care in Rural Appalachia
Sustaining Home Palliative Care for Patients With Heart Failure (HF) and Their Family Caregivers in Rural Appalachia: A Mixed Methods Randomized Clinical Trial (RCT).
Study Overview
Status
Intervention / Treatment
Detailed Description
This study uses a randomized control trial (RCT) design to test the integrated nurse-led intervention bundle of home palliative care intervention (HF-FamPALhomeCARE) for patients with heart failure (HF) and their family caregivers. (104 patient-family caregiver dyads).
The researcher will compare HF-FamPALhomeCARE to the standard control group to see if the participants in HF-FamPALhomeCARE group will report better health outcomes than the standard control group at the completion of the study at 12 months.
Aim 1: Compared to the control group at 3, 6, 9 months, and 1-year follow-up:
Hypothesis 1a. The patients in the intervention group will have higher scores on HF-related health quality-of-life measure and on the World Health Organization (WHO) aging functional health well-being scale.
Hypothesis 1b. The family caregivers in the intervention group will have higher scores on the World Health Organization (WHO) aging functional health well-being scale.
Aim 2: Compared to the control group at 3, 6, 9 months, and 1-year follow-up:
Hypothesis 2a. The patients in the intervention group will have (a) lower depression and anxiety scores and (b) higher numbers of signed EOL advance directives.
Hypothesis 2b. The family caregivers in the intervention group will have (a) lower depression and anxiety scores, (b) lower home caregiving burden scores, and (c) improved home HF EOLPC preparedness and improved home palliative care scores.
All participants receive standard care, which is routine HF instruction from their care providers. The HF-FamPALhomeCARE group receives 5-session intervention includes 2 home visits, and 3 bi-weekly telephone calls on HF home EOLPC care. Three follow-up telephone calls will be provided at 3, 6, 9, and 12 months. Control subjects will receive the same HF home care information after 12-month. Data collection for both groups are conducted at baseline, 3, 6, 9, and 12 months.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ubolrat Piamjariyakul
- Phone Number: 304.293.6729
- Email: ubolrat.piamjariyakul@hsc.wvu.edu
Study Contact Backup
- Name: Stephanie Young
- Phone Number: 304.581.1802
- Email: sayers1@hsc.wvu.edu
Study Locations
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Recruiting
- West Virginia University Hospital
-
Contact:
- Stephanie Young, MS
- Email: sayers1@hsc.wvu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult patients' age between 50 to 80 years with advanced HF (NYHA III or IV), diagnosed by physician
- Caregivers' age between 45 to 80 years.
- Alert and consent to participate
- Able to read and understand English
Exclusion Criteria:
- Already received or are on a waiting list for a heart transplant or left ventricular assist device (LVAD)
- Diagnosed with a terminal illness or dementia, such as Alzheimer's disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control
Participants in control group receive standard care which is routine HF instruction at primary providers or specialist's clinic appointments.
|
|
|
Experimental: HF-FamPALhomeCARE
HF-FamPALcare intervention group will receive standard care plus 2 home visits and 3 bi-weekly telephone calls on HF home EOLPC care, and follow-up telephone calls at 3, 6, 9, and 12 months.
|
Participants in HF-FamPALhomeCARE Intervention group receive standard care plus 2 home visits, 3 bi-weekly telephone call on HF home EOLPC care, and follow-up telephone calls at 3, 6, 9, and 12 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient's Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
Time Frame: Baseline
|
Measures patients' Heart Failure (HF) status & physical function status.
Each item is scored on a scale from 0 to 4 or 0 to 5, depending on the question.
The overall score range is 0-100 with a higher score indicating better HF health status.
|
Baseline
|
|
Patient's Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
Time Frame: 3 Month Follow up
|
Measures patients' Heart Failure (HF) status & physical function status.
Each item is scored on a scale from 0 to 4 or 0 to 5, depending on the question.
The overall score range is 0-100 with a higher score indicating better HF health status.
|
3 Month Follow up
|
|
Patient's Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
Time Frame: 6 Month Follow up
|
Measures patients' Heart Failure (HF) status & physical function status.
Each item is scored on a scale from 0 to 4 or 0 to 5, depending on the question.
The overall score range is 0-100 with a higher score indicating better HF health status.
|
6 Month Follow up
|
|
Patient's Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
Time Frame: 9 Month Follow up
|
Measures patients' Heart Failure (HF) status & physical function status.
Each item is scored on a scale from 0 to 4 or 0 to 5, depending on the question.
The overall score range is 0-100 with a higher score indicating better HF health status.
|
9 Month Follow up
|
|
Patient's Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
Time Frame: 12 Month Follow Up
|
Measures patients' Heart Failure (HF) status & physical function status.
Each item is scored on a scale from 0 to 4 or 0 to 5, depending on the question.
The overall score range is 0-100 with a higher score indicating better HF health status.
|
12 Month Follow Up
|
|
Patient--World Health Organization Quality of life Questionnaire
Time Frame: Baseline
|
Self-assessment that measures patient's function health and well-being.
Score range is 0-100 with a higher score indicating better health function and well-being.
|
Baseline
|
|
Patient--World Health Organization Quality of life Questionnaire
Time Frame: 3 Month Follow up
|
Self-assessment that measures patient's function health and well-being.
Score range is 0-100 with a higher score indicating better health function and well-being.
|
3 Month Follow up
|
|
Patient--World Health Organization Quality of life Questionnaire
Time Frame: 6 Month Follow up
|
Self-assessment that measures patient's function health and well-being.
Score range is 0-100 with a higher score indicating better health function and well-being.
|
6 Month Follow up
|
|
Patient--World Health Organization Quality of life Questionnaire
Time Frame: 9 Month Follow up
|
Self-assessment that measures patient's function health and well-being.
Score range is 0-100 with a higher score indicating better health function and well-being.
|
9 Month Follow up
|
|
Patient--World Health Organization Quality of life Questionnaire
Time Frame: 12 Month Follow up
|
Self-assessment that measures patient's function health and well-being.
Score range is 0-100 with a higher score indicating better health function and well-being.
|
12 Month Follow up
|
|
Caregiver--World Health Organization Quality of life Questionnaire
Time Frame: Baseline
|
Self-assessment that measures patient's function health and well-being.
Score range is 0-100 with a higher score indicating better health function and well-being.
|
Baseline
|
|
Caregiver--World Health Organization Quality of life Questionnaire
Time Frame: 3 Month Follow up
|
Self-assessment that measures patient's function health and well-being.
Score range is 0-100 with a higher score indicating better health function and well-being.
|
3 Month Follow up
|
|
Caregiver--World Health Organization Quality of life Questionnaire
Time Frame: 6 Month Follow up
|
Self-assessment that measures patient's function health and well-being.
Score range is 0-100 with a higher score indicating better health function and well-being.
|
6 Month Follow up
|
|
Caregiver--World Health Organization Quality of life Questionnaire
Time Frame: 9 Month Follow up
|
Self-assessment that measures patient's function health and well-being.
Score range is 0-100 with a higher score indicating better health function and well-being.
|
9 Month Follow up
|
|
Caregiver--World Health Organization Quality of life Questionnaire
Time Frame: 12 Month Follow up
|
Self-assessment that measures patient's function health and well-being.
Score range is 0-100 with a higher score indicating better health function and well-being.
|
12 Month Follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient--Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline
|
Patient Assessed: The Patient Health Questionnaire-9 (PHQ-9) is a self-administered tool used to screen, diagnose, and measure the severity of depression.
It consists of nine questions with each question scored from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
The total score ranges from 0 to 27, with higher scores indicating greater depressive symptoms.
|
Baseline
|
|
Patient--Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 3 Month Follow up
|
Patient Assessed: The Patient Health Questionnaire-9 (PHQ-9) is a self-administered tool used to screen, diagnose, and measure the severity of depression.
It consists of nine questions with each question scored from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
The total score ranges from 0 to 27, with higher scores indicating greater depressive symptoms.
|
3 Month Follow up
|
|
Patient--Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 6 Month Follow up
|
Patient Assessed: The Patient Health Questionnaire-9 (PHQ-9) is a self-administered tool used to screen, diagnose, and measure the severity of depression.
It consists of nine questions with each question scored from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
The total score ranges from 0 to 27, with higher scores indicating greater depressive symptoms.
|
6 Month Follow up
|
|
Patient--Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 9 Month Follow up
|
Patient Assessed: The Patient Health Questionnaire-9 (PHQ-9) is a self-administered tool used to screen, diagnose, and measure the severity of depression.
It consists of nine questions with each question scored from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
The total score ranges from 0 to 27, with higher scores indicating greater depressive symptoms.
|
9 Month Follow up
|
|
Patient--Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 12 Month Follow up
|
Patient Assessed: The Patient Health Questionnaire-9 (PHQ-9) is a self-administered tool used to screen, diagnose, and measure the severity of depression.
It consists of nine questions with each question scored from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
The total score ranges from 0 to 27, with higher scores indicating greater depressive symptoms.
|
12 Month Follow up
|
|
Caregiver--Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline
|
Caregiver Assessed: The Patient Health Questionnaire-9 (PHQ-9) is a self-administered tool used to screen, diagnose, and measure the severity of depression.
It consists of nine questions with each question scored from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
The total score ranges from 0 to 27, with higher scores indicating greater depressive symptoms.
|
Baseline
|
|
Caregiver--Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 3 Month Follow up
|
Caregiver Assessed: The Patient Health Questionnaire-9 (PHQ-9) is a self-administered tool used to screen, diagnose, and measure the severity of depression.
It consists of nine questions with each question scored from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
The total score ranges from 0 to 27, with higher scores indicating greater depressive symptoms.
|
3 Month Follow up
|
|
Caregiver--Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 6 Month Follow up
|
Caregiver Assessed: The Patient Health Questionnaire-9 (PHQ-9) is a self-administered tool used to screen, diagnose, and measure the severity of depression.
It consists of nine questions with each question scored from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
The total score ranges from 0 to 27, with higher scores indicating greater depressive symptoms.
|
6 Month Follow up
|
|
Caregiver--Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 9 Month Follow up
|
Caregiver Assessed: The Patient Health Questionnaire-9 (PHQ-9) is a self-administered tool used to screen, diagnose, and measure the severity of depression.
It consists of nine questions with each question scored from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
The total score ranges from 0 to 27, with higher scores indicating greater depressive symptoms.
|
9 Month Follow up
|
|
Caregiver--Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 12 Month Follow up
|
Caregiver Assessed: The Patient Health Questionnaire-9 (PHQ-9) is a self-administered tool used to screen, diagnose, and measure the severity of depression.
It consists of nine questions with each question scored from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
The total score ranges from 0 to 27, with higher scores indicating greater depressive symptoms.
|
12 Month Follow up
|
|
Patient--Generalized anxiety disorder (GAD-7)
Time Frame: Baseline
|
Patient Assessed: The Generalized Anxiety Disorder 7-item (GAD-7) scale is a self-administered questionnaire designed to screen for and measure the severity of generalized anxiety disorder (GAD).
It consists of seven items that assess how often the respondent has been bothered by various anxiety symptoms.
Each item is scored on a scale from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
Overall score range of 0-21 with a higher score indicating greater anxiety symptoms.
|
Baseline
|
|
Patient--Generalized anxiety disorder (GAD-7)
Time Frame: 3 Month Follow up
|
Patient Assessed: The Generalized Anxiety Disorder 7-item (GAD-7) scale is a self-administered questionnaire designed to screen for and measure the severity of generalized anxiety disorder (GAD).
It consists of seven items that assess how often the respondent has been bothered by various anxiety symptoms.
Each item is scored on a scale from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
Overall score range of 0-21 with a higher score indicating greater anxiety symptoms.
|
3 Month Follow up
|
|
Patient--Generalized anxiety disorder (GAD-7)
Time Frame: 6 Month Follow up
|
Patient Assessed: The Generalized Anxiety Disorder 7-item (GAD-7) scale is a self-administered questionnaire designed to screen for and measure the severity of generalized anxiety disorder (GAD).
It consists of seven items that assess how often the respondent has been bothered by various anxiety symptoms.
Each item is scored on a scale from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
Overall score range of 0-21 with a higher score indicating greater anxiety symptoms.
|
6 Month Follow up
|
|
Patient--Generalized anxiety disorder (GAD-7)
Time Frame: 9 Month Follow up
|
Patient Assessed: The Generalized Anxiety Disorder 7-item (GAD-7) scale is a self-administered questionnaire designed to screen for and measure the severity of generalized anxiety disorder (GAD).
It consists of seven items that assess how often the respondent has been bothered by various anxiety symptoms.
Each item is scored on a scale from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
Overall score range of 0-21 with a higher score indicating greater anxiety symptoms.
|
9 Month Follow up
|
|
Patient--Generalized anxiety disorder (GAD-7)
Time Frame: 12 Month Follow up
|
Patient Assessed: The Generalized Anxiety Disorder 7-item (GAD-7) scale is a self-administered questionnaire designed to screen for and measure the severity of generalized anxiety disorder (GAD).
It consists of seven items that assess how often the respondent has been bothered by various anxiety symptoms.
Each item is scored on a scale from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
Overall score range of 0-21 with a higher score indicating greater anxiety symptoms.
|
12 Month Follow up
|
|
Caregiver--Generalized anxiety disorder (GAD-7)
Time Frame: Baseline
|
Caregiver Assessed: The Generalized Anxiety Disorder 7-item (GAD-7) scale is a self-administered questionnaire designed to screen for and measure the severity of generalized anxiety disorder (GAD).
It consists of seven items that assess how often the respondent has been bothered by various anxiety symptoms.
Each item is scored on a scale from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
Overall score range of 0-21 with a higher score indicating greater anxiety symptoms.
|
Baseline
|
|
Caregiver--Generalized anxiety disorder (GAD-7)
Time Frame: 3 Month Follow up
|
Caregiver Assessed: The Generalized Anxiety Disorder 7-item (GAD-7) scale is a self-administered questionnaire designed to screen for and measure the severity of generalized anxiety disorder (GAD).
It consists of seven items that assess how often the respondent has been bothered by various anxiety symptoms.
Each item is scored on a scale from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
Overall score range of 0-21 with a higher score indicating greater anxiety symptoms.
|
3 Month Follow up
|
|
Caregiver--Generalized anxiety disorder (GAD-7)
Time Frame: 6 Month Follow up
|
Caregiver Assessed: The Generalized Anxiety Disorder 7-item (GAD-7) scale is a self-administered questionnaire designed to screen for and measure the severity of generalized anxiety disorder (GAD).
It consists of seven items that assess how often the respondent has been bothered by various anxiety symptoms.
Each item is scored on a scale from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
Overall score range of 0-21 with a higher score indicating greater anxiety symptoms.
|
6 Month Follow up
|
|
Caregiver--Generalized anxiety disorder (GAD-7)
Time Frame: 9 Month Follow up
|
Caregiver Assessed: The Generalized Anxiety Disorder 7-item (GAD-7) scale is a self-administered questionnaire designed to screen for and measure the severity of generalized anxiety disorder (GAD).
It consists of seven items that assess how often the respondent has been bothered by various anxiety symptoms.
Each item is scored on a scale from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
Overall score range of 0-21 with a higher score indicating greater anxiety symptoms.
|
9 Month Follow up
|
|
Caregiver--Generalized anxiety disorder (GAD-7)
Time Frame: 12 Month Follow up
|
Caregiver Assessed: The Generalized Anxiety Disorder 7-item (GAD-7) scale is a self-administered questionnaire designed to screen for and measure the severity of generalized anxiety disorder (GAD).
It consists of seven items that assess how often the respondent has been bothered by various anxiety symptoms.
Each item is scored on a scale from 0 to 3 (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day).
Overall score range of 0-21 with a higher score indicating greater anxiety symptoms.
|
12 Month Follow up
|
|
Patient--Integrated Palliative care Outcome Scale (IPOS)
Time Frame: Baseline
|
Patient reported: Integrated Palliative care Outcome Scale (IPOS) is a holistic assessment used to measure the symptoms and concerns of patients receiving palliative care.
Each item is scored based on the patient's response, typically on a scale from 0 to 4 with an overall score range of 0 to 68.
A higher overall score indicates more palliative care problems or concerns.
|
Baseline
|
|
Patient--Integrated Palliative care Outcome Scale (IPOS)
Time Frame: 3 Month Follow up
|
Patient reported: Integrated Palliative care Outcome Scale (IPOS) is a holistic assessment used to measure the symptoms and concerns of patients receiving palliative care.
Each item is scored based on the patient's response, typically on a scale from 0 to 4 with an overall score range of 0 to 68.
A higher overall score indicates more palliative care problems or concerns.
|
3 Month Follow up
|
|
Patient--Integrated Palliative care Outcome Scale (IPOS)
Time Frame: 6 Month Follow up
|
Patient reported: Integrated Palliative care Outcome Scale (IPOS) is a holistic assessment used to measure the symptoms and concerns of patients receiving palliative care.
Each item is scored based on the patient's response, typically on a scale from 0 to 4 with an overall score range of 0 to 68.
A higher overall score indicates more palliative care problems or concerns.
|
6 Month Follow up
|
|
Patient--Integrated Palliative care Outcome Scale (IPOS)
Time Frame: 9 Month Follow up
|
Patient reported: Integrated Palliative care Outcome Scale (IPOS) is a holistic assessment used to measure the symptoms and concerns of patients receiving palliative care.
Each item is scored based on the patient's response, typically on a scale from 0 to 4 with an overall score range of 0 to 68.
A higher overall score indicates more palliative care problems or concerns.
|
9 Month Follow up
|
|
Patient--Integrated Palliative care Outcome Scale (IPOS)
Time Frame: 12 Month Follow up
|
Patient reported: Integrated Palliative care Outcome Scale (IPOS) is a holistic assessment used to measure the symptoms and concerns of patients receiving palliative care.
Each item is scored based on the patient's response, typically on a scale from 0 to 4 with an overall score range of 0 to 68.
A higher overall score indicates more palliative care problems or concerns.
|
12 Month Follow up
|
|
Caregiver--Integrated Palliative care Outcome Scale (IPOS)
Time Frame: Baseline
|
Caregiver reported: Integrated Palliative care Outcome Scale (IPOS) is a holistic assessment used to measure the symptoms and concerns of caregivers receiving palliative care.
Each item is scored based on the patient's response, typically on a scale from 0 to 4 with an overall score range of 0 to 68.
A higher overall score indicates more palliative care problems or concerns.
|
Baseline
|
|
Caregiver--Integrated Palliative care Outcome Scale (IPOS)
Time Frame: 3 Month Follow up
|
Caregiver reported: Integrated Palliative care Outcome Scale (IPOS) is a holistic assessment used to measure the symptoms and concerns of caregivers receiving palliative care.
Each item is scored based on the patient's response, typically on a scale from 0 to 4 with an overall score range of 0 to 68.
A higher overall score indicates more palliative care problems or concerns.
|
3 Month Follow up
|
|
Caregiver--Integrated Palliative care Outcome Scale (IPOS)
Time Frame: 6 Month Follow up
|
Caregiver reported: Integrated Palliative care Outcome Scale (IPOS) is a holistic assessment used to measure the symptoms and concerns of caregivers receiving palliative care.
Each item is scored based on the patient's response, typically on a scale from 0 to 4 with an overall score range of 0 to 68.
A higher overall score indicates more palliative care problems or concerns.
|
6 Month Follow up
|
|
Caregiver--Integrated Palliative care Outcome Scale (IPOS)
Time Frame: 9 Month Follow up
|
Caregiver reported: Integrated Palliative care Outcome Scale (IPOS) is a holistic assessment used to measure the symptoms and concerns of caregivers receiving palliative care.
Each item is scored based on the patient's response, typically on a scale from 0 to 4 with an overall score range of 0 to 68.
A higher overall score indicates more palliative care problems or concerns.
|
9 Month Follow up
|
|
Caregiver--Integrated Palliative care Outcome Scale (IPOS)
Time Frame: 12 Month Follow up
|
Caregiver reported: Integrated Palliative care Outcome Scale (IPOS) is a holistic assessment used to measure the symptoms and concerns of caregivers receiving palliative care.
Each item is scored based on the patient's response, typically on a scale from 0 to 4 with an overall score range of 0 to 68.
A higher overall score indicates more palliative care problems or concerns.
|
12 Month Follow up
|
|
Patient--Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-12)
Time Frame: Baseline
|
Assessment of spiritual well-being of patient managing chronic health conditions.
Consists of 12 items with each item rated on a 5-point Likert scale, ranging from 0 (not at all) to 4 (very much).
Total score range is 0 to 48 with higher score indicating higher spiritual well-being.
|
Baseline
|
|
Patient--Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-12)
Time Frame: 3 Month Follow up
|
Assessment of spiritual well-being of patient managing chronic health conditions.
Consists of 12 items with each item rated on a 5-point Likert scale, ranging from 0 (not at all) to 4 (very much).
Total score range is 0 to 48 with higher score indicating higher spiritual well-being.
|
3 Month Follow up
|
|
Patient--Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-12)
Time Frame: 6 Month Follow up
|
Assessment of spiritual well-being of patient managing chronic health conditions.
Consists of 12 items with each item rated on a 5-point Likert scale, ranging from 0 (not at all) to 4 (very much).
Total score range is 0 to 48 with higher score indicating higher spiritual well-being.
|
6 Month Follow up
|
|
Patient--Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-12)
Time Frame: 9 Month Follow up
|
Assessment of spiritual well-being of patient managing chronic health conditions.
Consists of 12 items with each item rated on a 5-point Likert scale, ranging from 0 (not at all) to 4 (very much).
Total score range is 0 to 48 with higher score indicating higher spiritual well-being.
|
9 Month Follow up
|
|
Patient--Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-12)
Time Frame: 12 Month Follow up
|
Assessment of spiritual well-being of patient managing chronic health conditions.
Consists of 12 items with each item rated on a 5-point Likert scale, ranging from 0 (not at all) to 4 (very much).
Total score range is 0 to 48 with higher score indicating higher spiritual well-being.
|
12 Month Follow up
|
|
Caregiver--Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-12)
Time Frame: Baseline
|
Assessment of spiritual well-being of caregiver managing chronic health conditions.
Consists of 12 items with each item rated on a 5-point Likert scale, ranging from 0 (not at all) to 4 (very much).
Total score range is 0 to 48 with higher score indicating higher spiritual well-being.
|
Baseline
|
|
Caregiver--Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-12)
Time Frame: 3 Month Follow up
|
Assessment of spiritual well-being of caregiver managing chronic health conditions.
Consists of 12 items with each item rated on a 5-point Likert scale, ranging from 0 (not at all) to 4 (very much).
Total score range is 0 to 48 with higher score indicating higher spiritual well-being.
|
3 Month Follow up
|
|
Caregiver--Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-12)
Time Frame: 6 Month Follow up
|
Assessment of spiritual well-being of caregiver managing chronic health conditions.
Consists of 12 items with each item rated on a 5-point Likert scale, ranging from 0 (not at all) to 4 (very much).
Total score range is 0 to 48 with higher score indicating higher spiritual well-being.
|
6 Month Follow up
|
|
Caregiver--Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-12)
Time Frame: 9 Month Follow up
|
Assessment of spiritual well-being of caregiver managing chronic health conditions.
Consists of 12 items with each item rated on a 5-point Likert scale, ranging from 0 (not at all) to 4 (very much).
Total score range is 0 to 48 with higher score indicating higher spiritual well-being.
|
9 Month Follow up
|
|
Caregiver--Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-12)
Time Frame: 12 Month Follow up
|
Assessment of spiritual well-being of caregiver managing chronic health conditions.
Consists of 12 items with each item rated on a 5-point Likert scale, ranging from 0 (not at all) to 4 (very much).
Total score range is 0 to 48 with higher score indicating higher spiritual well-being.
|
12 Month Follow up
|
|
The Zarit Burden Interview (ZBI-12)
Time Frame: Baseline
|
The ZBI-12 consists of 12 questions that caregivers answer based on how often they experience certain feelings related to their caregiving role.
Each question is scored on a scale from 0 (never) to 4 (nearly always), with the total score ranging from 0 to 48 with a higher score indicating greater burden.
|
Baseline
|
|
The Zarit Burden Interview (ZBI-12)
Time Frame: 3 Month Follow up
|
The ZBI-12 consists of 12 questions that caregivers answer based on how often they experience certain feelings related to their caregiving role.
Each question is scored on a scale from 0 (never) to 4 (nearly always), with the total score ranging from 0 to 48 with a higher score indicating greater burden.
|
3 Month Follow up
|
|
The Zarit Burden Interview (ZBI-12)
Time Frame: 6 Month Follow up
|
The ZBI-12 consists of 12 questions that caregivers answer based on how often they experience certain feelings related to their caregiving role.
Each question is scored on a scale from 0 (never) to 4 (nearly always), with the total score ranging from 0 to 48 with a higher score indicating greater burden.
|
6 Month Follow up
|
|
The Zarit Burden Interview (ZBI-12)
Time Frame: 9 Month Follow up
|
The ZBI-12 consists of 12 questions that caregivers answer based on how often they experience certain feelings related to their caregiving role.
Each question is scored on a scale from 0 (never) to 4 (nearly always), with the total score ranging from 0 to 48 with a higher score indicating greater burden.
|
9 Month Follow up
|
|
The Zarit Burden Interview (ZBI-12)
Time Frame: 12 Month Follow up
|
The ZBI-12 consists of 12 questions that caregivers answer based on how often they experience certain feelings related to their caregiving role.
Each question is scored on a scale from 0 (never) to 4 (nearly always), with the total score ranging from 0 to 48 with a higher score indicating greater burden.
|
12 Month Follow up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ubolrat Piamjariyakul, West Virginia University School of Nursing
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2408021376
- R01NR021630 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
Study protocol and SAP will be shared via ClinicalTrials.gov and published protocol manuscript.
The Analysis codes will be made available at the end of the project period and at the time of publication.
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure NYHA Class III
-
CVRx, Inc.Enrolling by invitationHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class IIIUnited States
-
Foundry Innovation & Research 1, Limited (FIRE1)NAMSA; Baim Institute for Clinical ResearchNot yet recruitingHeart Failure | NYHA Class III Heart Failure | NYHA Class II Heart Failure
-
Vanderbilt University Medical CenterWithdrawnHeart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IUnited States
-
Northwell HealthRecruiting
-
University Hospital, Gentofte, CopenhagenUnknownChronic Heart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVDenmark
-
Comunicare Solutions SAKU Leuven; Jessa Hospital; Cliniques universitaires Saint-Luc- Université Catholique... and other collaboratorsRecruitingHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVBelgium
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVUnited States
-
Indiana UniversityCompletedHeart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IUnited States
-
Elpen Pharmaceutical Co. Inc.WithdrawnHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IV
-
Ahmad Abdullah SalawiCompletedHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IVSaudi Arabia
Clinical Trials on HF-FamPALhomeCARE
-
VA Office of Research and DevelopmentCompleted
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting
-
Texas Christian UniversityUnknownBody Weight ChangesUnited States
-
Abbott Medical DevicesCompleted
-
University of WaterlooThe Hong Kong Polytechnic University; University of Waterloo School of Optometry...Not yet recruitingGlaucoma | Mobility Limitation | Low Vision, Both Eyes | Retinitis Pigmentosa (RP) | Visually Impaired Persons | Orientation | Mobility Difficulty | Vision Loss Partial | Rod Cone Dystrophy | Peripheral Visual Field Defect of Both Eyes | Mobility and IndependenceCanada
-
Population Health Research InstituteMcMaster University; Hamilton Health Sciences CorporationRecruitingHeart FailureCanada, Tunisia
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownEnd Stage Renal DiseaseSpain, France, Italy, Belgium
-
The University of Hong KongHospital Authority, Hong KongCompletedHeart Failure | Telerehabilitation | Self Care | Empowerment | Disease ManagementHong Kong
-
Boston Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of Colorado, DenverPatient-Centered Outcomes Research Institute; Northwestern University; Yale University and other collaboratorsRecruitingHeart Failure With Reduced Ejection FractionUnited States